Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
Introduction to Hemostasis01:05

Introduction to Hemostasis

15.3K
Hemostasis is a complex physiological process that prevents excessive bleeding when a blood vessel is injured. It's crucial for maintaining the integrity of the circulatory system, as it ensures that our blood remains fluid while still within the vascular network and yet clots to prevent blood loss upon vessel injury.
The three phases of hemostasis involve many clotting factors present in plasma and several substances released by platelets and injured tissue cells. It is a fast, localized,...
15.3K
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

14.0K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
14.0K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

1.4K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.4K
Formation of the Platelet Plug01:22

Formation of the Platelet Plug

10.0K
The platelet phase, the second stage of hemostasis, commences around 15-20 seconds after an injury. It follows and overlaps with the vascular phase, during which blood vessels constrict to minimize blood loss.
As the injured blood vessel contracts, endothelial cells undergo contraction, revealing collagen fibers in the basement membrane and underlying connective tissue. Furthermore, the plasma membrane of endothelial cells becomes adhesive, preparing the site for platelet adhesion. Platelets...
10.0K
Vascular Spasm01:16

Vascular Spasm

4.2K
The vascular phase, also known as vasospasm, is the initial stage of hemostasis, crucial for preventing excessive bleeding when a blood vessel is injured. After a vessel is cut, nerves in the damaged area trigger pain and other sensory impulses. Simultaneously, the smooth muscles in the vessel wall contract, resulting in a vascular spasm. This contraction reduces the vessel's diameter at the injury site, slowing or stopping blood loss through the vessel wall. Vascular spasms typically last...
4.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Oppositely Charged Single Enzyme Nanogels Form Versatile Coacervates for Efficient Enzyme Cascade Catalysis.

Advanced materials (Deerfield Beach, Fla.)·2026
Same author

Engineering a Transmembrane Receptor for Coacervate-Based Artificial Cells.

Journal of the American Chemical Society·2026
Same author

Heterocoagulation of Inorganic Pigments for Solvent-Based Recycling of Polystyrene.

ChemSusChem·2026
Same author

Converging frontiers in biomolecular condensate and synthetic cell research.

npj biomedical innovations·2026
Same author

Bio-Propelled Stomatocyte Nanomotors with Glutathione-Responsiveness for Osteoarthritis Treatment.

Angewandte Chemie (International ed. in English)·2026
Same author

Gradient Copolymers: A Complex Comonomer Incorporation Reality behind the Perfect Ideal.

ACS polymers Au·2026

Related Experiment Video

Updated: Feb 26, 2026

TAPE: A Biodegradable Hemostatic Glue Inspired by a Ubiquitous Compound in Plants for Surgical Application
08:40

TAPE: A Biodegradable Hemostatic Glue Inspired by a Ubiquitous Compound in Plants for Surgical Application

Published on: June 8, 2016

14.7K

Next Generation Hemostatic Materials Based on NHS-Ester Functionalized Poly(2-oxazoline)s.

Marcel A Boerman1,2,3, Edwin Roozen4, María José Sánchez-Fernández2,3

  • 1Institute for Molecules and Materials (IMM), Radboud University Nijmegen , Heyendaalseweg 135, 6525 AJ Nijmegen, The Netherlands.

Biomacromolecules
|July 13, 2017
PubMed
Summary
This summary is machine-generated.

A novel synthetic hemostatic patch using N-hydroxysuccinimide ester-functional poly(2-oxazoline)s (POx-NHS) effectively seals wounds. This nonbioactive polymer demonstrates superior hemostatic efficacy compared to existing clinical products.

More Related Videos

Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting
08:53

Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting

Published on: March 28, 2025

827
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.6K

Related Experiment Videos

Last Updated: Feb 26, 2026

TAPE: A Biodegradable Hemostatic Glue Inspired by a Ubiquitous Compound in Plants for Surgical Application
08:40

TAPE: A Biodegradable Hemostatic Glue Inspired by a Ubiquitous Compound in Plants for Surgical Application

Published on: June 8, 2016

14.7K
Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting
08:53

Artificial Lung Device Priming for In Situ Fiber Bundle Surface Grafting

Published on: March 28, 2025

827
Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.6K

Area of Science:

  • Biomaterials Science
  • Surgical Innovation
  • Polymer Chemistry

Background:

  • Hemostatic agents are crucial for surgical hemorrhage control, but current options exhibit variable efficacy and reliance on natural sources, limiting reproducibility.
  • Existing bioactive and hybrid hemostatic devices face challenges such as irregular cross-linking and dissolution under substantial blood flow.
  • There is a need for reproducible, synthetic hemostatic materials that ensure consistent performance in diverse surgical conditions.

Purpose of the Study:

  • To develop and evaluate a novel synthetic, nonbioactive hemostatic product based on N-hydroxysuccinimide ester-functional poly(2-oxazoline)s (POx-NHS) coated onto gelatin patches.
  • To investigate the mechanism of action, focusing on the formation of covalent cross-links for wound sealing and hemorrhage prevention.
  • To compare the hemostatic efficacy of the developed POx-NHS patches against established clinical products, Hemopatch and Tachosil.

Main Methods:

  • Coating of N-hydroxysuccinimide ester-functional poly(2-oxazoline)s (POx-NHS) onto gelatin patches to create a hybrid hemostatic device.
  • Systematic study of process parameters including polymer type, carrier material, and coating technique.
  • In vitro and in vivo testing of POx-NHS powders and coated patches to assess hemostatic efficacy.
  • Direct comparative analysis against commercially available hemostatic products (Hemopatch and Tachosil).

Main Results:

  • The developed POx-NHS coated gelatin patches effectively form covalent cross-links between the polymer, blood proteins, gelatin, and tissue, leading to robust wound sealing.
  • Both POx-NHS polymer powders and coated patches demonstrated significant hemostatic efficacy in vitro.
  • In vivo studies confirmed the superior hemostatic performance of POx-NHS patches compared to Hemopatch and Tachosil.
  • The synthetic nature of POx-NHS ensures reproducibility, overcoming limitations of natural source-dependent hemostatic agents.

Conclusions:

  • N-hydroxysuccinimide ester-functional poly(2-oxazoline)s (POx-NHS) represent a promising synthetic, nonbioactive material for next-generation hemostatic patches.
  • The covalent cross-linking mechanism provides effective and reliable hemorrhage control during surgical procedures.
  • POx-NHS coated gelatin patches offer a reproducible and potentially superior alternative to current clinical hemostatic devices.